Novo Nordisk's Drug for Obesity Treatment Gets FDA Panel Approval

September 12, 2014 1:53 PM

8 0

Novo Nordisk's Drug for Obesity Treatment Gets FDA Panel Approval

U.S. Food and Drug Administration advisers have backed Novo Nordisk's drug liraglutide for obesity treatment.

The drug was voted 14-1 by the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of FDA. The panel said that the benefits of the injectable drug outweigh its harms and that the federal agency might consider approving liraglutide for the treatment of obesity.

Read more

To category page

Loading...